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Globally, asthma is one of the most common chronic conditions that affect individuals
of all ages. When poorly controlled, it negatively impacts patient’s ability to enjoy life
and work. At the population level, effective use of recommended strategies in children
and adults can reduce symptom burden, improve quality of life and significantly reduce
the risk of exacerbation, decline of lung function and asthma-related death. Inhaled
corticosteroid as the initial maintenance therapy, ideally started within 2 years of symptom
onset, is highly effective in both children and adults and across various degrees of asthma
severity. If asthma is not controlled, the choice of subsequent add-on therapies differs
between children and adults. Evidence supporting pharmacological approach to asthma
management, especially for those with more severe disease, is more robust in adults
compared to children. This is, in part, due to various challenges in the diagnosis of
asthma, in the recruitment into clinical trials and in the lack of objective outcomes in
children, especially those in the preschool age group. Nevertheless, where evidence is
emerging for younger children, it seems to mirror the observations in adults. Clinicians
need to develop strategies to implement guideline-based recommendations while taking
into consideration individual variations in asthma clinical phenotypes, pathophysiology
and treatment responses at different ages.
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INTRODUCTION
Asthma Burden
Asthma is a chronic inflammatory disease of the airways with typical symptoms of wheezing,
breathlessness and cough and variable airflow obstruction. The WHO estimates that some 235
million people currently suffer from asthma (1) and it is the commonest chronic disease of children
worldwide. Asthma causes long term effects: it affects patient’s quality of life, daily activities, their
work and school attendance; it causes anxiety—to the patients themselves, and to their families and
caregivers; it imposes a substantial economic burden on families and societies; and it causes death.
Yet, with appropriate management most people with asthma can enjoy excellent symptom control
and a good quality of life (1).
Control of asthma symptoms, reduction of future risk in terms of asthma attacks, and prevention
of decline in lung function are recognized as the key goals of asthmamanagement (Figure 1). These
goals are relevant to all patients with asthma irrespective of age. Pharmacological therapies are
the main tools for controlling asthma but non-pharmacological interventions such as allergen or
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FIGURE 1 | Aims of asthma management.
irritant (especially tobacco smoke) avoidance, and education
about the disease, inhaler device use and self-management
strategies are also important.
Asthma Phenotypes
There is increasing recognition of different clinical and patho-
physiological patterns of asthma (‘phenotypes’) in both children
and adults.
The most striking asthma phenotype is found in young
children who present with wheezing attacks associated with
viral infection, particularly rhinovirus infection, often with no
symptoms between attacks. For many of these children, the
wheezing attacks stop in later childhood (2). In older children,
a more classic asthma pattern of attacks with chronic interval
symptoms usually with an atopic background emerges (3).
However, these patterns overlap and are unstable, at least in early
childhood, andmay change from one to another over times scales
as short as a year (4, 5). Lung function testing in young children is
generally not possible and making a diagnosis of asthma without
objective testing has been criticized (6). The implications for the
choice of treatments of the different phenotypes is complex and
has resulted in a wide variety of approaches often compounded
by a lack of evidence (7).
In adults, the pattern of airway inflammation is more diverse
and the clinical presentation is often clouded by co-existing
comorbidities especially in those with severe asthma (8, 9).
Currently an emerging concept, but an important focus of asthma
management in adults is the identification and management
of pulmonary, extrapulmonary and behavioral “treatable traits”.
The hope is that treatment of these modifiable elements (e.g.,
bronchodilator reversibility, eosinophilic airway inflammation,
depression) even in the absence of a deeper understanding of
the mechanisms of airway inflammation will improve patient
outcomes (10). Although the concept of treatable traits has been
developed in relation to adults it is also likely to be useful in
children with asthma.
There are some patients, both adult and children, with
“discordant” disease who suffer substantial symptom burden
with little evidence of eosinophilic inflammation or those with
high level of inflammation but few symptoms (11). However,
the majority of patients will have asthma symptoms that
parallel the degree of inflammation in which step-wise guideline
recommended approach is likely to be effective.
This review summarizes evidence about differences in the
approaches to asthma treatments in adults and children as
currently recommended in commonly used asthma guidelines
(12, 13) (Table 1).
GUIDELINE RECOMMENDED APPROACH
FOR CHRONIC ASTHMA
Step 1: As Needed SABA
For patients of all ages, as needed short acting beta2 agonist
(SABA) reliever therapy is highly effective for rapid relief
of asthma symptoms. SABA as the sole treatment is now
only recommended for those with the mild and intermittent
symptoms (<2 per week and no nocturnal awakenings), no
history of asthma attacks in the previous year and normal
lung function.
Historically, there has been a perception that patients with
intermittent symptoms are not at risk of asthma attacks, a view
increasingly challenged. Evidence from adult studies showed that
airways inflammation occurs at a very early stage of the disease
even in patients with intermittent asthma, albeit at a lower level
than in those with persistent asthma (14, 15). Furthermore,
early introduction of once daily inhaled corticosteroid (ICS)
in adults and children > 5years with mild asthma symptoms
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TABLE 1 | Comparison of recommended treatments for chronic asthma in adults and children from widely used international guidelines (12, 13).
Asthma guideline
treatment steps
Similarities in recommendations Differences in recommendations, effectiveness or safety
profile
Step 1 • As needed SABA effective for all ages
• Consider early use of ICS for adults and children ≥ 6
years old
Step 2 • Regular low dose ICS for all ages • Potential concern for effect of ICS on linear growth in children
• Intermittent ICS may improve symptom control in adults and
adolescents
• Intermittent ICS in children < 5 years with viral induced
wheezing reduces the risk of severe asthma attacks.
Step 3 • Regular ICS recommended for all age groups
• LTRA inferior to LABA or higher dose ICS in adults and
children respectively
• Allergen immunotherapy limited to carefully selected
adults and children.
• Addition of LABA to low dose ICS as first preferred option in
adolescents and adults
• Moderate dose ICS preferred in children
• Concern for LTRA-related neuropsychiatric effects in children and
adolescents
• ICS/formoterol as single maintenance and reliever therapy is
another option for adolescents and adults; insufficient evidence
for use in children <12 years old
Step 4 • ICS/LABA + SABA prn or ICS/fomoterol as single
maintenance and reliever therapy recommended for
adults and adolescents.
• Higher dose ICS monotherapy provides little additional
benefit in children and adults
• Tiotropium is a safe, alternative add-on therapy for
adults and adolescents; emerging supportive data for
younger children
• Theophylline no longer recommended for adults
and children.
• Insufficient data for ICS/formoterol as single inhaler therapy use
in children <12 years old
• Specialist review recommended for children
Step 5 • Referral to specialist recommended for all ages
• Review of medication adherence, comorbidities and
risk factors important for all ages groups
• Anti-IgE monoclonal therapy can be used for patients
≥ 6 years old
• Anti-IL5 monoclonal therapy (mepolizumab) can be
used in patients ≥18 years old and has been
approved for use in children ≥ 6 years
• Use of anti-IL5 (mepolizumab) more extensively researched in
adolescents and adults; use of younger children (≥ 6years old)
approved based on extrapolated data.
• Other advanced therapies such as macrolides and bronchial
thermoplasty are recommended for adults; lacks data in
children or adolescents.
ICS, inhaled corticosteroid; LABA, long acting beta2 agonist; LTRA, leukotriene receptor antagonist; SABA, short acting beta2 agonist.
reduced the risk of severe asthma exacerbation by almost half,
with better asthma control although it did not affect lung
function (16, 17).
This has led widely used international guidelines (12, 13)
to update their recommendation for the consideration of
ICS use as Step 1 treatment in all adults, adolescents and
children over 6 years with mild asthma, even those with
infrequent symptoms, to reduce the risk of severe, potentially
life-threatening exacerbations (18–20).
Step 2: Regular Low Dose ICS Plus as
Needed SABA
Adults and Children (Age >5years)
Regular low dose ICS significantly improves lung function,
quality of life and reduces asthma exacerbations in both adults
and children with mild persistent asthma (13, 18). O’Byrne et
al showed that introduction of low dose budesonide reduced the
risk of asthma exacerbation by 60% and improved asthma control
days by half (19). Selected studies in adults also showed less
rescue SABA use (18). It was suggested that duration of therapy
of at least 4 weeks may be an important determinant of overall
treatment response (18).
The greatest benefits of ICS in adults and children older than 5
years old have been achievedwhen ICS therapy was started within
2 years of symptom onset (21, 22); this effectively halved the
overall risk of severe or life-threatening exacerbations (16, 17).
After this time, higher ICS doses are required for adults and
there is a negative correlation between duration of symptoms
and maximal increases in lung function (22–24). Low dose ICS
appears protective against potential long-term decline in lung
function following severe exacerbations. Interestingly, this effect
is only seen in adults and children but not adolescents (25).
It is unclear if this is due to the relatively small number of
adolescents studied or relates to the improvements in asthma that
have been noted during adolescence (26). Early initiation of ICS
also improves asthma control and diminished subsequent needs
for additional maintenance therapy (24).
One important difference in children compared with adults
is a persistent concern about the impact of regular ICS in
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children on linear growth. As an example, in the START study
Pauwels et al. reported that children aged 5–15years treated with
budesonide showed reduced growth especially in the first year
of treatment (16). However, other studies found that children
attain normal projected adult height while on prolonged inhaled
budesonide (21, 22).
The evidence on linear growth in children treated with ICS has
recently been updated to take account of newer inhaled steroid
molecules. The regular use of ICS at low or medium daily doses
was found to be associated with statistically significant growth
suppression during a 1-year treatment period in children with
mild to moderate persistent asthma. The mean growth reduction
was 0.48 cm/year in linear growth velocity and 0.61 cm change
from baseline height during a one year treatment period. ICS-
induced growth suppression appears to be maximal during the
first year of treatment and less pronounced in subsequent years
and appears to be more strongly associated with ICS molecule
than with the device or dose in the low to medium dose range
(27). A second review looking at dose response effects found
a small but statistically significant group difference in growth
velocity between low doses and low to medium doses, favoring
the use of low-dose ICS (28). Thus the evidence confirms the
relative safety of ICS in relation to growth effects but supports the
use of the lowest effective dose of ICS, with regular monitoring
of linear growth. It is surprising how many gaps still exist in the
current evidence base about ICS and growth (29).
Preschool Children (Age <5years)
There is also strong and consistent evidence to support the use
of daily ICS for preventing exacerbations in preschool children
with recurrent wheeze, especially in those with persistent asthma
symptoms (30). The effect of ICS appears to be stronger in
those with a diagnosis of asthma compared with recurrent
wheezing and is independent of age (pre-schoolers vs. infants),
atopic condition, type of ICS, and mode of delivery (spacer vs.
nebulizer) (31).
The evidence about growth suppression in pre-school children
is limited. Nevertheless, because of concerns about side effects,
an important question is whether ICS therapy can be targeted
to those children most likely to respond? One recent study in
children requiring step 2 treatment showed that while individual
treatment responses were phenotypically diverse, children with
aeroallergen sensitization and increased blood eosinophil counts
responded best to a daily ICS as opposed to a leukotriene
receptor antagonist (LTRA) or as needed-ICS. Daily ICS was
associated withmore asthma control days and fewer exacerbation
(32). However, a very recent real-world study of large matched
cohort analysis of anonymized UK medical record data found
no evidence that stepping up therapy by adding ICS or
monteleukast, compared with as-needed use of SABA, reduced
wheezing/asthma attacks in a diverse population of preschool
children with at least two documented prior wheezing episodes
(33). In the absence of better tools to help target treatments, and
in light of improved outcomes over time in preschool children
a “wait-and-see approach” may be a clinically prudent approach
for many with infrequent, intermittent attacks.
Alternative Options
Low Dose Combination ICS/Long Acting Beta2
Agonist (LABA)
For steroid-naïve adults and adolescents with mild persistent
asthma, ICS/LABA works faster in achieving GINA-defined good
asthma control compared to ICS alone. However, there is little
difference in exacerbation rate between the two therapies. In
practice, the additional cost for ICS/LABA compared to low
dose ICS may be an important consideration for the individual
patient (34). Data as to whether there would be similar benefits
in children is not available.
Intermittent ICS Regimes
Regular use of ICS raises concerns from patients and clinicians
about adherence and steroid side effects. Poor adherence to
ICS potentially results in patients relying on SABAs to control
symptoms, possibly resulting in overuse.
Recently, it was shown that adults and adolescents with
mild asthma using as-needed combination ICS and fast acting
LABA had better asthma symptom control measured by an
electronic diary compared to as-needed SABA (35). However,
the magnitude of effect was inferior to regular low dose ICS
therapy. A second trial in a similar cohort reported no difference
in exacerbation rate when comparing ICS/formoterol as needed
vs. regular ICS (36).
There is less evidence about the use of as needed ICS treatment
in children. One study in children from 5 years upwards with
mild well-controlled asthma stepping down from daily ICS found
ICS and SABAs as needed more effective at reducing attacks than
SABA use alone (37). Liner growth was 1.1 cm a year less when
ICS was used regularly but not when used on an as needed basis.
In children under 5 years, the most common asthma
phenotype is intermittent viral triggered wheezing attacks with
no interval symptoms. In this group, intermittent ICS, usually as
high-dose ICS at the first sign of an URTI for 7 to 10 days led
to a 35% reduction in severe attacks (30). Intermittent ICS were
associated with greater linear growth of 0.41 cm per year (i.e., less
growth suppression) compared with daily treatment (38).
Oral Leukotriene Receptor Antagonist (LTRA) in
Preschool Children
Because of concerns about ICS side effects and difficulties using
inhaled therapies in young children, oral montelukast has been
widely prescribed as an alternative to regular ICS. While early
studies showed it to be effective, the most recent review found no
evidence of benefit from the use of montelukast, continuously or
intermittently on the number of wheezing episodes, unscheduled
medical attendance, or oral corticosteroid use in preschool
children with recurrent wheeze (39). There is also little evidence
of benefit for other secondary outcomes (7).
Step 3: One or two Maintenance
Treatments Plus as Needed
Reliever Therapy
For adults and adolescents with suboptimal symptom control or
more than 1 exacerbation in the previous year despite treatment
with low dose ICS, guidelines recommend low dose ICS/LABA
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as maintenance therapy plus SABA or ICS/formoterol as single
inhaler therapy (12, 13). In children, at present, moderate dose
ICS plus as needed SABA is the preferred treatment for children.
ICS/LABA Maintenance Plus SABA as Required
Historically, there were concerns that LABA may mask airway
inflammation leading to potential adverse events including
asthma exacerbations. To the contrary, the addition of LABA
to ICS significantly increases the odds of achieving good overall
asthma control as defined by guidelines (34). Combination low
dose ICS/LABA therapy was highly effective at reducing the
risk of exacerbations needing oral corticosteroid (19, 40, 41)
and hospitalizations (40, 42, 43) in symptomatic adults and
adolescents with mild to moderate asthma compared to ICS
alone. The addition of LABA also leads to improvement in
lung function (especially in those with lower baseline FEV1),
proportion of symptom-free days (19, 44) and a slight reduction
in rescue SABA use compared to same or higher dose of
ICS (41, 43).
The advantages of adding a LABA have been less clear in
children. In children with persistent asthma, the addition of
LABA to ICS was not associated with a significant reduction in
the rate of exacerbations requiring systemic steroids, but it was
superior for improving lung function compared with the same
or higher doses of ICS. There were no differences in adverse
effects, with the exception of significantly lower linear growth
over a year in the children treated with a higher ICS dose, with
a mean difference of 1.21cm/yr. A trend toward an increased risk
of hospital admission with LABA, irrespective of the dose of ICS,
was noted as a matter for concern (45).
ICS/Formoterol as Single Maintenance and
Reliever Therapy
Combination of ICS with formoterol as fast acting
bronchodilator allows patients to use their regular maintenance
inhaler also for rapid relief of symptoms. Single inhaler therapy
is more effective at reducing mild to moderate exacerbations
while providing similar levels of asthma control compared with
medium dose ICS monotherapy or fixed dose of ICS/LABA and
as required SABA (46–50). It has been suggested that using single
inhaler for both maintenance and reliever therapy may improve
adherence but definitive data is lacking.
The role of single maintenance and reliever therapy in
children age 12 years and below is unclear at present and requires
further study. It is not currently licensed for use in this way in
this age group.
Alternative Treatment Options
Higher dose ICS
At the population level, further escalation to higher dose ICS
use in adults and adolescents provides little added benefit but
rather greater adrenal suppression (51, 52). Higher dose of
ICS is inferior to combination ICS/LABA in reducing the risk
of exacerbations requiring oral corticosteroids. Combination
therapy is also superior in improving lung function, symptom
control, and use of rescue SABA than a higher dose of ICS
alone (44, 47).
In the past, written action plans commonly included advice
about a temporary increase in inhaled steroid dose—usually
doubling—in the early stages of an asthma exacerbation to reduce
the severity of the attack and to prevent the need for oral steroids
or hospital admission. The accumulated evidence suggested that
this doubling approach was not effective (53).
However, the concept of intermittent ICS dose escalation to
prevent asthma exacerbations has recently been revisited in two
large studies. In a pragmatic and unblinded trial, McKeever
et al. randomized adults and adolescents (N = 1922) on ICS
maintenance therapy to receive a personalized management plan
that included a temporary quadrupling of ICS when asthma
control started to deteriorate compared to remaining on their
usual ICS dose (54). They showed that a temporary quadrupling
at the time of worsening asthma control resulted in a lower
rate of severe exacerbations of asthma than no increase in the
dose (45% vs. 52%).
In contrast, Jackson et al. studied children 5 to 11 years of age
(n = 254) with mild to moderate asthma already on low dose
ICS therapy and reported no difference in rates of exacerbation
in those treated with quintupled dose of ICS compared with their
usual ICS dose at the earliest sign of asthma deterioration (55).
The reasons for the differences in outcomes between these
two studies are not completely clear. Differences in the size
of study cohort and fewer than expected exacerbations in the
pediatric study may be one reason and there may be differences
in pathophysiology during exacerbations between adults and
children. A more plausible explanation may lie in the fact the
study by McKeever et al. was a pragmatic open label study with
no monitoring of compliance. Increasing the ICS dose at the
start of an exacerbation may have merely resulted in the patients
starting a treatment they had been poorly compliant with before.
In contrast, Jackson’s study was a randomized control trial with
electronic diary recording of treatment. Diary completion was
> 70% during usual treatment and rose to around 98% of the
days during the treatment (55, 56). Thus there may have been no
headroom for a further impact of the increased ICS dose.
Given the bioequivalence dose of inhaled to oral
corticosteroid and subsequent potential effects on adrenal
suppression, it is also debatable whether the very high
steroid dose used in the quadrupling or quintupling
approach is necessarily better than a standard course of oral
prednisolone (57).
Leukotriene receptor antagonists (LTRA)
Leukotriene receptor antagonists inhibit the pro-inflammatory
effect of leukotrienes not completely suppressed by corticosteroid
therapy. The addition of LTRA to symptomatic adult asthmatics
already treated with regular ICS monotherapy leads to
reduced exacerbations, better asthma control and better
lung function (58, 59).
It is unclear if LTRA is superior to higher doses of ICS
monotherapy (58) except in adults with aspirin-intolerant
asthma. However, asthma symptoms, lung function, and rescue
medication use are improved when LTRA is added to high doses
of ICS (60). In this specific patient cohort, aspirin desensitization
is also a safe, and effective option (61).
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The addition of LTRA is less effective than adding LABA to
ICS when one looks at comparative benefits in lung function,
asthma symptoms, rescue medication use, and asthma related
quality of life (62). The effect on oral corticosteroid-treated
exacerbation was statistically superior with the addition of LABA
than LTRA to ICS but with only an absolute difference of 2%
between groups. However, this meta-analysis was dominated by
16 trials that included 6872 adults and adolescents; only 2 studies
included 336 children (age 6–17 years). As such, it is unclear
which adjunct therapy is best for children.
An earlier Cochrane 2013 analysis concluded there was no
difference in asthma exacerbations needing oral corticosteroid or
hospitalization comparing LTRA to same or higher dose ICS in
children and adolescents with mild to moderate asthma (63). The
paucity of randomized trials and heterogeneity in study design
and reporting of published studies make it difficult to support
its use as add-on therapy in children with moderate asthma
(step 3 treatment).
In preschool children, there are as yet no trials comparing
LTRA, or LABA, as an add on therapy to ICS.
Neuropsychiatric side effects have been reported as not
uncommon in young children started on montelukast. One
study (n = 106) found montelukast had been stopped in
16% of children because of neuropsychiatric effects (irritability,
aggressiveness, and sleep disturbance), mostly within 2 weeks
of starting therapy (64). Long term use in adults is not
recommended unless there is clear symptomatic improvement
after a trial of therapy (65).
Allergen immunotherapy
Allergen immunotherapy (AIT) is still the only-disease
modifying treatment strategy for IgE-mediated allergic disease
(66). Studies using both subcutaneous (SCIT) and sublingual
treatments (SLIT) have shown some benefit in reducing asthma
symptoms and bronchial hyper-reactivity in adults and children.
GINA guideline recommend SLIT for adults with rhinitis
and allergy to house dust mite with exacerbations despite
ICS, provided FEV1 is > 70% predicted (12). It reduces
exacerbation rates in adults with moderate asthma but has
minimal effect on asthma symptom control or quality of
life (67). Its role in adults with compromised lung function
requires further clarification. In a randomized control trial
of subjects 14 years or older with mild to moderate asthma,
those treated with sublingual house dust mite immunotherapy
were able to reduce their ICS dose while maintaining asthma
control (68).
In children, the most up to date evidence noted that
there were no studies that evaluated asthma symptom using
a validated tool and both study characteristics and outcomes
were reported heterogeneously. There is moderate-strength
evidence that SCIT may reduce long term asthma controller
medication use in children with allergic asthma (68). Studies
of SLIT have only studied children with mild/moderate asthma
mono-sensitized to house dust mite. Local and systemic
allergic reactions were common but anaphylaxis was reported
rarely (69).
Current recommendations advise that allergen
immunotherapy should not be given to patients with severe
or uncontrolled asthma who are at increased risk for systemic
reactions (70).
Step 4: Two or More Maintenance
Therapies Plus as Needed
Reliever Medication
For adults and adolescents whose asthma is inadequately
controlled on low dose ICS/LABA maintenance therapy, the two
recommended step-up approaches are low dose ICS/formoterol
single maintenance and reliever therapy or medium dose
ICS/LABA asmaintenance plus as needed SABA (44). In contrast,
for children < 12 years old because of concerns regarding
medication side effects and the lack of sound evidence base,
current guidelines recommend referral for specialist review (12).
Post hoc analysis of five large clinical trials suggests that
ICS/formoterol as single maintenance and reliever inhaler may
be the preferred option compared to guideline recommended
treatment for various stages of asthma severity using low dose
ICSmonotherapy or same or higher fixed dose ICS/LABA regime
(50). The magnitude of difference is more marked for those
with more severe disease requiring GINA Step 4 treatment.
Single maintenance and inhaler therapy prolongs the time to
first exacerbation and reduces the overall risk of exacerbations
at relatively low doses of ICS compared with higher fixed dose
of ICS/LABA and as-needed SABA (46, 47, 50). The effect on
hospitalization is less clear. Secondary outcomes such as lung
function, rescue SABA use, symptom free days, and quality of life
were also superior for single maintenance and reliever therapy
than higher fixed dose ICS/LABA regime.
Again, the best option in children younger than 12 years old is
unclear due to insufficient data.
Alternative and/or Additional Treatment Options
Several alternative options are available for adults and
adolescents. However, robust data for their use in younger
children is again currently lacking.
High dose ICS/LABA
While high dose ICS/LABA may be considered in adults and
adolescents, the increase in ICS dose generally provides little
additional benefit (34, 41, 71), and there is an increased risk of
side effects, including adrenal suppression (72). A high dose is
recommended only on a trial basis for up to 6 months when good
asthma control cannot be achieved with medium dose ICS/LABA
and /or a third controller (12).
Long acting muscarinic antagonist (LAMA)
The long-acting anticholinergic tiotropium, delivered once daily
via a mist inhaler, is approved for the treatment of asthma in the
EU and the USA with the license recently extended to include
children with severe asthma over 6 years of age. The GINA
guidelines currently position tiotropium as an add on therapy
option at step 4 in patients aged ≥12years with a history of
exacerbations (12).
Frontiers in Pediatrics | www.frontiersin.org 6 March 2019 | Volume 7 | Article 62
Chung and Paton Treatment of Chronic Asthma in Children and Adults
For adults treated with ICS, LAMA prescribed as add on
therapy has been shown to reduce the risk of exacerbations
and improve lung function but made no difference in quality
of life (73). In a study of 210 moderate asthmatics, tiotropium
bromide added to ICS offered marginal improvements in peak
flow and symptoms compared to doubling dose of ICS. The effect
was considered non-inferior to salmeterol. However, there was
the possibility of carry-over effects due to the cross-over design
(74, 75). Cochrane analysis of 3 trials (76–78) comparing addition
of tiotropium mist inhaler in adults with severe asthma already
treated with ICS/LABA combination therapy showed definitive
improvement in trough FEV1 and fewer exacerbations (79).
In children over 6 years with symptomatic moderate or
severe asthma, tiotropium treatment led to improvement in
lung function and asthma control (80), similar to that found in
adult studies. However, the data in children is less extensive and
generally short term with the longest study lasting 48 weeks (81).
In younger children, one small 12 week RCT of children aged
1–5years study showed tiotropium was safe, led to a reduction
in asthma attacks but did not improve daily asthma symptom
scores. These findings need to be confirmed in larger studies (82).
Both in adults and children tiotropium has a safety profile
comparable to placebo.
Theophylline
The addition of slow release theophylline to low dose budesonide
for moderate asthma is just as effective as high dose budesonide
in improving lung function and reducing symptoms and rescue
SABA use in adults but has little effect on exacerbation rate
over 3 months duration (83). Theophylline is a less effective
bronchodilator than beta2 agonists and associated with high risk
of adverse effects.
In the past, oral xanthines were used as a first line preventer
treatment (at Step 2) for children with asthma. Although there is
weak evidence that theophyllines were better than placebo, they
are no longer used because ICS were shown to be more effective
at improving symptoms and reducing asthma attacks (84). When
low dose ICS fail to control asthma, oral theophyllines have been
used as one of the available add-on options and there is weak
evidence that adding theophylline to ICS treatment improves
symptom control and reduces exacerbations (85). However,
current recommendations are that theophyllines should only be
tried when the addition of LABA and LTRA have both failed.
Theophyllines have adverse effects including headaches and
nausea if therapeutic concentrations are exceeded. There are also
significant interactions with some commonly used drugs which
inhibit theophylline clearance e.g., erythromycin which can result
in increased theophylline levels and resulting toxicity.
Step 5: Refer for Expert Review and
Add-On Therapy
The great majority of adults with severe asthma not responding
to high dose treatments are “difficult-to-treat” because of
comorbidities and risk factors that mimic or worsen asthma
control (86, 87) and the management of these other factors is as
important as the asthma treatments in improving the outcomes
of patients with severe asthma. The situation is similar in children
where only the minority will have genuinely therapy resistant
asthma (88).
Poor adherence with treatment is a particularly important
cause of difficult to treat asthma in both adults and children.
Improving adherence is difficult. A variety of interventions
have been shown to lead to improvements including adherence
education, the use of electronic trackers or reminders, simplified
drug regimens and school-based directly observed therapy.
However, because of uncertain and inconsistent impact on
clinical outcomes such as quality of life and asthma control
the clinical relevance of the improvements has been less clear
with many studies affected by concerns about risk of bias and
inconsistency (89). Themost recent studies in adults and children
have shown that a combination of electronic monitoring and
biofeedback can improve adherence and asthma outcomes (90–
92). In one adult study, a programme of adherence and inhaler
technique assessment resulted in only 27% remaining refractory
to their asthma treatment (92). Hence, such approaches may offer
a more effective approach in the future.
A number of add-on options are available for those with
severe therapy resistant asthma. But prior to the use of these
therapies, it is important to follow a systematic approach in
the assessment and management of “difficult-to-treat” severe
asthma—to confirm diagnosis, address poor adherence and to
identify and manage comorbidities and risk factors (93, 94).
The following add-on options are best reserved for well-
phenotyped patients with “severe treatment-refractory” asthma.
The bulk of the evidence for their use at present is in adults
and adolescents.
Anti-IgE Monoclonal Therapy
Omalizumab can be used for adults and children over 6 years of
age with inadequately controlled severe allergic asthma despite
optimized therapies (12, 13). The published datamostly related to
adolescents and adults with only 3 randomized studies exclusive
to children or adolescents (95–97). Most of the published
data included subjects with moderate to severe asthma where
omalizumab appears equally effective across different ages at
reducing the risk of exacerbations and hospitalizations (98–100).
Benefits are also seen in asthma symptom control for adults
and children whilst other outcomes such as quality of life and
rescue medication use have mainly been assessed in adults with
modest improvements.
In addition, omalizumab allows for reduction or withdrawal
of inhaled corticosteroid use but the latter option must be
considered with caution (98). In children with severe disease
omalizumab can reduce the burden of corticosteroids (101) and
might be an effective alternative to oral corticosteroids (OCS)
although a large direct OCS-sparing trial in children is required
to confirm this.
In clinical use in both adults and children omalizumab has
proved safe with few serious adverse effects (98).
Anti-interleukin 5 (IL-5) Monoclonal Therapy
Newer therapies targeted at IL-5 (mepolizumab, reslizumab) or
the IL-5 receptor (benralizumab) are effective for adolescents
and adults with severe eosinophilic asthma at high risk of
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exacerbations or with high symptom burden despite high dose
ICS and another maintenance therapy (102). The effectiveness
of subcutaneous mepolizumab (103, 104) and benralizumab
(105, 106) in reducing exacerbations and hospitalizations is well-
documented. They also improve asthma control, quality of life
with modest gain in lung function and reduce the need for oral
corticosteroid (106–108). Similar benefits were demonstrated
with reslizumab only when administered intravenously which
may impact its use in clinical practice (109, 110).
Randomized trials for all three anti-IL-5 therapies recruited
patients over 12 years and included a few adolescents; studies
using mepolizumab in children age between 6 and 11yr are
underway. The EMA has recently approved mepolizumab for use
in children 6–17years but this is based on an extrapolation of
data from the efficacy and safety data from the Phase III studies
in the mepolizumab severe asthma development programme for
patients 12 and over.
Possible Alternatives for Adults Not Included in
Guidelines: Macrolides, Bronchial Thermoplasty
Macrolides
Macrolides have antibacterial, antiviral and immunomodulatory
effects and are shown to be effective in different asthma
phenotypes (111). Adults with persistent asthma despite two
or more maintenance therapies including ICS have fewer
exacerbations and better quality of life when treated with
azithromycin for 6-12months (111, 112). Macrolides are well–
tolerated but microbial resistance is a potential concern with long
term use. To date, there is no reported increase in infections
related to macrolide use.
At present, there is no evidence that regular treatment with
macrolides improves asthma control in children. Intermittent
use of azithromycin in preschool children at the time of
asthma attacks has been investigated. One study found that
Azithromycin shortened the duration of episodes of asthma-
like symptoms in young children aged 1–3years (113); in a
second study in preschool children presenting to an emergency
department, 5 days azithromycin (vs. placebo) neither reduced
the duration of respiratory symptoms nor time to respiratory
exacerbation in the following 6 months after treatment (114).
Bronchial thermoplasty
Bronchial thermoplasty is a non-pharmacological, endoscopic
treatment for subjects aged ≥18 years with severe persistent
asthma that is not well-controlled with ICS and LABA. Bronchial
thermoplasty provides lower rates of exacerbations and modest
improvements in quality of life but no difference in asthma
control scores in patients with moderate to severe asthma
(115–117). The procedure may be associated with temporary
deterioration in asthma control needing hospitalization but is not
associated with significant adverse respiratory effects on follow
up out with the treatment phase. Its role in adult patients with
severe asthma remains unclear especially in those with poor
lung function. Based on current data, bronchial thermoplasty is
not recommended by guidelines and it should only be used in
carefully considered patients in the setting of a registry to allow
independent data collection and in centers experienced in the
technique. At present, there is no data on the use of bronchial
thermoplasty in young people with severe asthma <18years
of age.
Chromones (nedocromial sodium and sodium cromoglycate)
Chromones have favorable safety profile but low clinical efficacy
compared to ICS in adults and children (118). The most recent
Cochrane systematic review of studies in children judged there
was insufficient evidence to be sure about the efficacy of sodium
chromoglycate over placebo and was concerned that publication
bias is likely to have overestimated the beneficial effects of sodium
chromoglycate as maintenance therapy in childhood asthma in
the past. They may have some role in those with exercise induced
bronchospasm who are unresponsive to SABA pre-exercise and
regular ICS for underlying asthma, as well as those intolerant of
bronchodilators (119).
Approach to Adjusting Maintenance
Treatment
Pharmacological management of asthma is based on continuous
cycle of assessment, treatment and review to allow up or down
titration of maintenance therapies to maximize patient outcomes
using minimal treatment at various stage of the disease (12, 13).
Control Based Treatment Adjustment
Most guidelines recommend a change in management based on
measures of symptom control with or without other risk factors
such as compromised lung function or a history of exacerbations.
Symptom based approaches are essentially all that is available in
young children because of the fact they cannot co-operate with
standard lung function tests.
For many patients in primary care, symptom control is a good
guide to reduced risk of exacerbations. However, it is important
to be mindful that in some patients, there may be discordance
between responses in symptom control and asthma attacks. In
preschool children, particularly, many children will have severe
attacks of wheezing but no symptoms in between attacks.
Alternative Strategies for Adjusting Asthma
Treatment Based on Eosinophilic Markers (Sputum
Eosinophil Count or Exhaled Nitric Oxide)
Airways inflammation in asthma can be predominantly
eosinophilic or non-eosinophilic. While ICS are the major
preventer treatment to control symptoms, ICS are more
effective in reducing symptoms in patients with eosinophilic
inflammation than in those with neutrophilic inflammation
(120). There has therefore been interest in whether
tailoring asthma treatment based on objective eosinophilic
inflammation improved asthma outcomes. Two approaches
have been used to date: examination of eosinophil counts
in induced sputum samples; or the measurement of exhaled
nitric oxide.
The most up-to-date synthesis of the evidence concluded
that children and adults randomized to either eosinophilic
marker strategy were significantly less likely to experience
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an exacerbation during the follow-up period (4.5–24months).
The exacerbation rate was also lower in adults with either
strategy compared to controls, but not in children. For both
strategies in adults and children, there was no difference for all
secondary outcomes (FEV1, asthma control test score, asthma
quality of life, beta agonist use). There was also no difference
in the final ICS use in either adults or children for either
strategy (121).
Exacerbations are one, albeit important, asthma outcome;
other outcomes such as symptom control and lung function
also need consideration. Why there is discrepancy between
exacerbations and other asthma outcomes is not understood
but it has been noted in other studies involving the newer
monoclonal drugs targeted at eosinophilic allergic pathways such
as mepolizumab (103).
Currently, sputum induction is restricted to laboratories
and clinics with specific expertise. It is technically
demanding and time consuming and not always successful,
particularly in younger children. Universal use of FeNO
would be a substantial extra cost if used for all asthma
patients and there is a yet no evidence-based algorithm
on how to adjust treatment based on FeNO levels. Such
an approach is most likely to benefit those with frequent
asthma exacerbations.
In studies limited to non-smoking adults, FeNO
>50ppb was predictive of good short-term response
to ICS (122). However, there are no studies
examining the long-term safety with regard to
exacerbations or withholding ICS in patients with low
initial FeNO.
Asthma Treatment at Different Ages –
Challenges to Asthma Guidelines
The evidence base for the management of children with
asthma, particularly young children, is often quite limited and
has been compounded by a number of problems. Children
under the age of 5–6years are usually not able to co-operate
with lung function test and as result objective outcomes
are commonly not available. Trials of treatment are more
problematic without objective outcomes. New drugs are usually
not tested in children until they have been extensively tested
in adult patients. Recruiting and retaining children and their
parents into randomized studies is difficult and as a result
trials are often more limited in scale and duration. The
consequence is that the evidence base for asthma treatments is
often much smaller than available for adults. However, when
an evidence base does emerge it is surprising how often it
mirrors the that from adult studies. The value of ICS in
preventing asthma exacerbations in young children would be an
obvious example.
Asthma Guidelines summarize “population level” evidence
and provide broad and generalized recommendations about
asthma management (12, 13). However, it is now accepted
that asthma is a heterogeneous disease and adjusting asthma
treatment that takes account of differing phenotypes is one of the
most important current challenges.
Despite publication of many evidence-based guidelines and
the availability of effective therapies, there is widespread
concern that asthma control in adults and children often
remains poor and that asthma attacks and even deaths
from asthma are not improving (123, 124). This is largely
because there is a need to take account of “patient level”
factors and tailor treatments to individuals. Such factors
include any individual characteristics, preferences, risk factors,
comorbidities or phenotype that predict or influence a patient’s
likely response to treatment, together with practical issues
such as ability to use a particular inhaler, adherence, and
affordability. Finally, patients with asthma, including children
and their parents, often have different treatment goals from
their physicians and want to balance the aims of optimizing
asthma management against the side effects or inconvenience
of taking regular medication necessary to achieve asthma
control (13).
CONCLUSION
Asthma can significantly impact on all facets of life for patients
across all age groups. Effectivemanagement strategies are broadly
summarized by local and international guidelines. Overall, the
evidence for pharmacological approach are more extensive
and more robust for adults than that for younger children.
For milder disease, the use of ICS as the initial maintenance
therapy and SABA as needed appears universally effective for
children, adolescents and adults. However, the preferred choice
of subsequent add-on therapies differs and the evidence base
for advanced therapeutic options is mostly based on studies
in adolescents and adults. Clinicians are currently challenged
with the need to develop management strategies that best
caters for individual differences in asthma presentation and
management. Accounting for differences in pathophysiological
mechanisms, asthma phenotypes and treatment responses
at different ages remains one of the most significant of
these challenges.
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